


Stabilis



Metoclopramide hydrochloride



Noms commerciaux

Afipran	Islande, Norvège
Aristopramida	Brésil
Cerucal	Allemagne, Hongrie
Clopan	Equateur, Italie
Clopram	Maroc, Tunisie
Clopritec	Mexique
Disgradon	Argentine
Doperan	Tunisie
Emperal	Danemark
Eucil	Brésil
Maxolon	Afrique du sud, Australie, Grande Bretagne
Meclomid	Mexique
Meclonir	Colombie, Equateur
Meclop	Mexique
Meclopram	Egypte
Metoclox	Equateur
Metogastron	Autriche
Metoplon	Turquie
Metotag	Argentine
Metpamid	Turquie
Paspertin	Autriche, Suisse
Perinorm	Afrique du sud
Plasil	Brésil, Colombie, Italie
Plemazol	Egypte
Pramadin	Vénézuela
Pramalon	Afrique du sud
Pramotil	Mexique
Primperan	Arabie Saoudite, Belgique, Colombie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Finlande, France, Grèce, Luxembourg, Malaisie, Maroc, Pays bas, Pérou, Portugal, Suède, Suisse, Tunisie, Turquie, Vénézuela
Primsel	Turquie
Reglan	Croatie, Etats Unis d'Amérique, Slovénie



Stabilité des solutions

		0,3 & 1 mg/ml	-20°C		150			1455
		0,3 & 1 mg/ml	4°C		150			1455
		0,5 mg/ml	25°C		21			1957
		5 mg/ml	23°C		60			180
		5 mg/ml	32°C		7			180
		5 mg/ml	4°C		90			180



Stabilité en mélange

		0,5 mg/ml	22°C		Morphine sulfate : 1 mg/ml	42		1495
		0,5 mg/ml	4°C		Morphine sulfate : 1 mg/ml	189		1495
		0,5 mg/ml	22°C		Morphine sulfate : 1 mg/ml	14		1495
		0,5 mg/ml	4°C		Morphine sulfate : 1 mg/ml	35		1495
		25 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2179
		0,15 mg/ml	32°C		Pethidine hydrochloride : 7.35 mg/ml	48		930
		0,5 mg/ml	22°C		Morphine sulfate : 1 mg/ml	42		1495
		0,5 mg/ml	4°C		Morphine sulfate : 1 mg/ml	189		1495
		0,1 mg/ml	4°C		Tramadol hydrochloride : 1 mg/ml	32		3082
		0,7 mg/ml	32°C		Midazolam hydrochloride : 0,6 mg/ml Fentanyl citrate : 40 µg/ml	10		1405
		0,5 mg/ml	22°C		Morphine sulfate : 1 mg/ml	42		1495
		2,5 mg/ml	23°C		Ondansetron hydrochloride : 1 mg/ml	24		815
		0,5 mg/ml	25°C		Haloperidol lactate : 0,5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,5 mg/ml	25°C		Famotidine : 0,4 mg/ml Ketoprofene : 1,5 mg Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,5 mg/ml	4°C		Morphine sulfate : 1 mg/ml	189		1495
		2,5 mg/ml	4°C		Ondansetron hydrochloride : 1 mg/ml	24		815
		0,5 mg/ml	4°C		Famotidine : 0,4 mg/ml Ketorolac tromethamine : 1,5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166

		0,86 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026
		1,6 mg/ml	25°C		Diphenhydramine hydrochloride : 2 mg/ml Dexamethasone sodium phosphate : 0,16 mg/ml	48		3779



Facteur influençant la stabilité

					301
	-20°C				180



Compatibilités

	Metoclopramide hydrochloride : 0.2 mg/ml Aciclovir sodium : 5 mg/ml		336
			2335
	Metoclopramide hydrochloride : 5 mg/ml Aldesleukin : 0.0338 MUI/ml		36
			307
	Metoclopramide hydrochloride : 5 mg/ml Amifostine : 10 mg/ml		3
	Metoclopramide hydrochloride : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
			921
			253
	Metoclopramide hydrochloride : 0,1 mg/ml Atosiban : 0,75 mg/ml		4642
	Metoclopramide hydrochloride : 5 mg/ml Aztreonam : 40 mg/ml		99
	Metoclopramide hydrochloride : 5 mg/ml Bivalirudin : 5 mg/ml		1713
	Metoclopramide hydrochloride : 5 mg/ml Caffeine : 10 mg/ml		3964
	Metoclopramide hydrochloride : 0.2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Metoclopramide hydrochloride : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Metoclopramide hydrochloride : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
			2269
		RL	2269

		Metoclopramide hydrochloride Ceftobiprole medocartil sodium		4650
		Metoclopramide hydrochloride : 0.2 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Metoclopramide hydrochloride : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
		Metoclopramide hydrochloride : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Metoclopramide hydrochloride : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Metoclopramide hydrochloride : 5 mg/ml Cladribine : 0.5 mg/ml		1496
		Metoclopramide hydrochloride : 5 mg/ml Cladribine : 0.015 mg/ml		1496
		Metoclopramide hydrochloride : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml		1971
		Metoclopramide hydrochloride : 5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Metoclopramide hydrochloride : 0.16 >> 0.45 mg/ml Diamorphine hydrochloride : 45.45 >> 145.16 mg/ml		1230
		Metoclopramide hydrochloride : 5 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Metoclopramide hydrochloride : 0.2 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Metoclopramide hydrochloride : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Metoclopramide hydrochloride : 5 mg/ml Doripenem : 5 mg/ml		2262
		Metoclopramide hydrochloride : 1 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
		Metoclopramide hydrochloride : 5 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
		Metoclopramide hydrochloride : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Metoclopramide hydrochloride : 5 mg/ml Droperidol : 2,5 mg/ml		763
		Metoclopramide hydrochloride : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Metoclopramide hydrochloride : 5 mg/ml Famotidine		397
		Metoclopramide hydrochloride : 5 mg/ml Famotidine : 2 mg/ml		215
		Metoclopramide hydrochloride : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Metoclopramide hydrochloride : 5 mg/ml Fentanyl citrate : 25 µg/ml		1974
		Metoclopramide hydrochloride : 5 mg/ml Filgrastim : 30 µg/ml		244
		Metoclopramide hydrochloride : 1 mg/ml Flucloxacillin sodium : 20 mg/ml		1232

	Metoclopramide hydrochloride : 5 mg/ml Fluconazole : 2 mg/ml		496
	Metoclopramide hydrochloride : 5 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Metoclopramide hydrochloride Fluorouracil		3474
	Metoclopramide hydrochloride : 0,1 mg/ml Fluorouracil : 2,5 mg/ml		153
	Metoclopramide hydrochloride : 5 mg/ml Fluorouracil : 50 mg/ml		763
	Metoclopramide hydrochloride : 5 mg/ml Folate calcium : 10 mg/ml		763
	Metoclopramide hydrochloride : 4 mg/ml Foscarnet sodium : 24 mg/ml		73
	Metoclopramide hydrochloride : 2 mg/ml Foscarnet sodium : 24 mg/ml	 	1135
	Metoclopramide hydrochloride : 0.2 mg/ml Fosfomycin : 30 mg/ml	 	4055
	Metoclopramide hydrochloride : 5 mg/ml Furosemide : 10 mg/ml		763
	Metoclopramide hydrochloride : 1 mg/ml Furosemide : 1 mg/ml		1232
	Metoclopramide hydrochloride : 5 mg/ml Gallium nitrate : 1 mg/ml		91
	Metoclopramide hydrochloride : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Metoclopramide hydrochloride : 5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Metoclopramide hydrochloride : 3 mg/ml Haloperidol lactate : 0.25 >> 0.5 mg/ml	 	4404
	Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Haloperidol lactate : 0.21 & 0.62 mg/ml		1971
	Metoclopramide hydrochloride : 5 mg/ml Heparin sodium : 1000 UI/ml		763
	Metoclopramide hydrochloride : 5 mg/ml Hetastarch : 60 mg/ml		1721
	Metoclopramide hydrochloride Hyaluronidase		3184
	Metoclopramide hydrochloride : 5 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
	Metoclopramide hydrochloride : 5 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
	Metoclopramide hydrochloride : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	 	4433
	Metoclopramide hydrochloride : 0.2 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	 	3829
	Metoclopramide hydrochloride : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
	Metoclopramide hydrochloride : 0.2 mg/ml Ketoprofene : 3.2 mg/ml		1847
	Metoclopramide hydrochloride : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625


	Metoclopramide hydrochloride : 5 mg/ml Levofloxacin : 5 mg/ml		1072
	Metoclopramide hydrochloride : 3 mg/ml Levomopromazine : 0.625 >> 2.5 mg/ml		4404
	Metoclopramide hydrochloride : 5 mg/ml Linezolid : 2 mg/ml		1925
	Metoclopramide hydrochloride : 5 mg/ml Melphalan : 0.1 mg/ml		169
	Metoclopramide hydrochloride : 5 mg/ml Meropenem : 1 & 50 mg/ml		266
	Metoclopramide hydrochloride : 0.1 mg/ml Meropenem : 1 & 20 mg/ml		266
	Metoclopramide hydrochloride : 5 mg/ml Meropenem : 50 mg/ml		4319
	Metoclopramide hydrochloride : 5 mg/ml Methadone hydrochloride : 1 mg/ml		1974
	Metoclopramide hydrochloride : 3 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
	Metoclopramide hydrochloride : 5 mg/ml Morphine sulfate : 1 mg/ml		1974
	Metoclopramide hydrochloride Morphine tartrate		519
	Metoclopramide hydrochloride : 0.58 mg/ml		3379
	Metoclopramide hydrochloride : 3 mg/ml Midazolam hydrochloride : 1.2 mg/ml		4404
	Metoclopramide hydrochloride : 3.33 mg/ml Midazolam hydrochloride : 1.67 mg/ml		404
	Metoclopramide hydrochloride : 0.5 mg/ml Morphine sulfate : 1 mg/ml		1495
	Metoclopramide hydrochloride : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Metoclopramide hydrochloride : 5 mg/ml		3948
	Metoclopramide hydrochloride : 5 mg/ml Methotrexate sodium : 25 mg/ml		763
	Metoclopramide hydrochloride Methotrexate sodium		3637
	Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Midazolam hydrochloride : 0.5 & 1.5 mg/ml		1971
	Metoclopramide hydrochloride : 3.33 mg/ml Morphine hydrochloride : 1.67 >> 10 mg/ml		1757
	Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971
	Metoclopramide hydrochloride : 0.2 mg/ml Morphine sulfate : 1 mg/ml		62
	Metoclopramide hydrochloride : 5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Metoclopramide hydrochloride : 2.5 mg/ml Ondansetron hydrochloride : 1 mg/ml		815
	Metoclopramide hydrochloride : 5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Metoclopramide hydrochloride : 1.2 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125

		Metoclopramide hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Metoclopramide hydrochloride : 1.2 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125
		Metoclopramide hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		4742
		Metoclopramide hydrochloride : 5 mg/ml		301
		Metoclopramide hydrochloride : 5 mg/ml	RL	4603
		Metoclopramide hydrochloride : 5 mg/ml		1415
		Metoclopramide hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Metoclopramide hydrochloride : 5 mg/ml Paclitaxel : 1.2 mg/ml		85
		Metoclopramide hydrochloride : 5 mg/ml		3948
		Metoclopramide hydrochloride : 50 mg/ml Palonosetron hydrochloride : 50 µg/ml	∅	2179
		Metoclopramide hydrochloride Pantoprazole sodium		2090
		Metoclopramide hydrochloride : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Metoclopramide hydrochloride : 0.2 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Metoclopramide hydrochloride : 0.15 mg/ml Pethidine hydrochloride : 7.35 mg/ml		930
		Metoclopramide hydrochloride : 6.67 mg/ml Pethidine hydrochloride : 16.67 mg/ml	∅	930
		Metoclopramide hydrochloride : 1 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Metoclopramide hydrochloride : 5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Metoclopramide hydrochloride : 0.2 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Metoclopramide hydrochloride : 0,1 mg/ml Posaconazole : 1,2 mg/ml		4521
		Metoclopramide hydrochloride : 5 mg/ml Propofol		660
		Metoclopramide hydrochloride : 5 mg/ml Propofol : 10 mg/ml	∅	300
		Metoclopramide hydrochloride : 5 mg/ml Quinupristine/dalfopristine : 2 mg/ml		1513
		Metoclopramide hydrochloride : 0,2 mg/ml Ranitidine hydrochloride : 1 mg/ml		3558
		Metoclopramide hydrochloride : 10 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
		Metoclopramide hydrochloride : 5 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Metoclopramide hydrochloride : 5 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Metoclopramide hydrochloride : 5 mg/ml Sargramostim : 10 µg/ml		335

	Metoclopramide hydrochloride : 3 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml		4404
	Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Scopolamine N-butyl bromide : 1.68 & 5 mg/ml		1971
	Metoclopramide hydrochloride : 5 mg/ml Sugammadex : 100 mg/ml		3372
	Metoclopramide hydrochloride : 0,2 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Metoclopramide hydrochloride : 0,2 mg/ml Tacrolimus : 1000 µg/ml		479
	Metoclopramide hydrochloride : 0.2 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Metoclopramide hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
	Metoclopramide hydrochloride : 5 mg/ml Teniposide : 0.1 mg/ml		905
			3767
	Metoclopramide hydrochloride : 5 mg/ml Thiopental sodium : 25 mg/ml		3767
	Metoclopramide hydrochloride : 5 mg/ml Thiotepa : 1 mg/ml		249
	Metoclopramide hydrochloride Tigecycline		3332
	Metoclopramide hydrochloride : 1.72 mg/ml Topotecan : 0.056 mg/ml		1026
	Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml		1971
	Metoclopramide hydrochloride : 0,1 mg/ml Tramadol hydrochloride : 1 mg/ml		3082
	Metoclopramide hydrochloride : 0.02 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Metoclopramide hydrochloride : 5 mg/ml Vinblastine sulfate : 1 mg/ml		763
	Metoclopramide hydrochloride : 5 mg/ml Vincristine sulfate : 1 mg/ml		763
	Metoclopramide hydrochloride : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Metoclopramide hydrochloride : 2 mg/ml Zidovudine : 4 mg/ml		337



Voie d'administration





Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
153	Revue	Wang DP, Chang LC, Lee DK. Stability of fluorouracil-metoclopramide hydrochloride admixture. Am J Health-Syst Pharm 1995 ; 52: 98-99.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
180	Revue	Zhang Y, Trissel LA, Martinez JF, Gilbert DL. Stability of metoclopramide hydrochloride in plastic syringes. Am J Health-Syst Pharm 1996 ; 53: 1300-1302.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.

337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
519	Revue	Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 316.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
763	Revue	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
930	Revue	Hor MMS, Chan SY, Yow KL, Lim LY, Chan E. Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. J Clin Pharm Ther 1997 ; 22: 339-345.
1026	Revue	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.

1072	Revue	Saltzman CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1230	Revue	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Revue	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1455	Revue	Demoré B, Raffy F, Commun N, Vigneron J, Hoffman MA, Hoffman M. Etude de la stabilité de deux benzamides antiémétiques en poches PVC de chlorure de sodium 0.9% et de glucose 5% sur une période de 5 mois. J Pharm Clin 1995 ; 14: 178-179.
1495	Revue	Nixon AR, O'Hare MCB, Chisakuta AM. The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations. Pharm J 1995 ; 254: 153-155.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1513	Laboratoire	Quinupristine / dalfopristine (Synecid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.

1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1757	Revue	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1847	Revue	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1957	Revue	Gupta VD. Chemical stability of metoclopramide hydrochloride injection diluted with 0.9% sodium chloride injection in polypropylene syringes at room temperature. Int J Pharm Compound 2005 ; 9, 1: 72-74.
1971	Revue	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2125	Revue	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.




























































2179	Revue	Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3082	Revue	Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5% polyolefin bag at 4°C. J Oncol Pharm Practice 2009 ; 15: 195-200.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3216	Revue	CP, Pham F, Viallet C, OME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3558	Revue	Rowe H, Riley J, Newby B. Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline. Can J Hosp Pharm 2013 ; 66, 5: 332.

3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3779	Revue	Kintzel P.E, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection Am J Health-Syst Pharm 2014 ; 71:2061-2065
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020

4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4642	Poster	Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. SEFH Congress (Virtual) October 2021 2021
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

 Antiémétique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 Chlorure de sodium 0,9%	 A l'abri de la lumière
 Jour	 Seringue polypropylène
 Non précisée	 Aucun
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Glucose 5%	 Heure
 NaCl 0,9% ou glucose 5%	 Polyéthylène
 Eau pour préparation injectable	 Lumière
 Non précisé	 Facteur influençant la stabilité
 Nutrition parentérale (mélange binaire)	 Provoque
 Dégradation	 Précipitation
 Compatibilités	 Compatible
 Précipitation immédiate	 Incompatible
 Précipitation en 15 minutes	 RL Ringer lactate
 Incompatibilité non précisée	 NaCl 0,9% + bactériostatique
 Turbidité immédiate	 Solvant spécifique
 Précipitation en 4 heures	 Perte de turbidité
 Nutrition parentérale (mélange ternaire)	 Instabilité de l'émulsion à 4 heures
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Perfusion continue
 Intramusculaire	 Sous cutanée
 Perfusion SC continue	 Bibliographie
 Dictionnaire	